Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 4/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1299145 | 0.98 | HTR2B (0.51) | PARP1HTR2BNPY5RKMT2APKM | |
| SCHEMBL1299363 | 0.90 | PARP1 (0.54) | PARP1HTR2BNPY5RKMT2APKM | |
| Carbamic Acid SCHEMBL28440834 | 0.90 | PARP1 (0.61) | PARP1HTR2B | |
| SCHEMBL2276872 | 0.89 | ALDH1A1 (0.59) | HTR2BNPY5RKMT2APKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL31596380 | 0.87 | MAPT (0.57) | HTR2BNPY5RKMT2APKMALDH1A1 | |
| SCHEMBL2674802 | 0.86 | HTR2B (0.55) | HTR2BNPY5RKMT2APOLBMAPT | |
| SCHEMBL6756134 | 0.86 | NPC1 (0.59) | HTR2BNPY5RKMT2APOLBMAPT | |
| SCHEMBL6757201 | 0.84 | NPC1 (0.62) | HTR2BNPY5RPOLBMAPT | |
| SCHEMBL724921 | 0.84 | NPC1 (0.62) | HTR2BNPY5RPOLBMAPT | |
| SCHEMBL2491336 | 0.83 | HTR2B (0.52) | HTR2BNPY5RKMT2APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924240-A | Synthesis process of 4- (1H-benzo [ D ] imidazole-2-yl) piperidine-1-carboxylic acid tert-butyl ester | 江苏恒沛药物科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-109694367-B | Method for preparing bilastine | 湖北省医药工业研究院有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-112110893-A | Preparation method of bilastine | 山东齐环医药科技有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-109206455-A | It is used to prepare the aryl ruthenium complex and its preparation method and application for the treatment of liver-cancer medicine | 广西中医药大学 | 2019-01-15 | — | — | CN | claimed |
| CN-109180741-A | Ruthenium (II) complex and its preparation method and application for treating gastric cancer | 广西中医药大学 | 2019-01-11 | — | — | CN | claimed |
| CN-108752390-A | With phototoxic antitumoral compounds and its preparation method and application | 广西中医药大学 | 2018-11-06 | — | — | CN | claimed |
| CN-107857702-A | A kind of preparation method of bilastine intermediate | 重庆华邦制药有限公司 | 2018-03-30 | — | — | CN | claimed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250273719-A1 | ION-EXCHANGE MEMBRANE, MEMBRANE ELECTRODE ASSEMBLY, CELL FOR REDOX FLOW BATTERY, AND REDOX FLOW BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-08-28 | — | — | US | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025129167-A1 | INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-114591292-B | Bilastine intermediate compounds | 鲁南制药集团股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-1181287-A1 | SULFONAMIDE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001029029-A1 | TETRAHYDROBENZINDOLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000073299-A1 | SULFONAMIDE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000037074-A1 | MUTILIN 14-ESTER DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-06-29 | — | — | WO | disclosed |
| US-5877187-A | Benzimidazole derivatives with antihistaminic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (FAES) (ES) | 1999-03-02 | — | — | US | disclosed |
| EP-0818454-A1 | Benzimidazole derivatives with antihistaminic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1998-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | PARP1 2479/4885HTR2B 11/4885NPY5R 21/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | PARP1 1831/4885HTR2B 4574/4885NPY5R 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.